Levetiracetam Monitoring in Epilepsy Management

Clinical Monitoring and Dosing Considerations

• The American Academy of Neurology recommends monitoring seizure frequency and characteristics as the primary endpoint, rather than serum levels, with a focus on clinical response to levetiracetam therapy in patients with epilepsy 1
• The American College of Clinical Pharmacology suggests assessing for adverse effects, such as somnolence, asthenia, CNS depression, and behavioral changes, in patients receiving levetiracetam, with a strength of evidence rated as high 1

Special Populations and Pharmacokinetics

• The National Kidney Foundation guidelines indicate that renal impairment is a primary situation requiring dose modification, as levetiracetam is 66% renally excreted unchanged, with a recommended dose adjustment for patients with mild, moderate, or severe renal impairment 1

Monitoring Keppra Levels in Epilepsy Patients

General Monitoring Guidelines

• Complete blood count monitoring is recommended when initiating levetiracetam therapy, as suggested by the American College of Emergency Physicians 2

Special Populations Requiring More Frequent Monitoring

• Patients with suspected non-adherence should be considered for level monitoring, according to the American College of Emergency Physicians 2